Imagine shedding pounds with the help of popular weight-loss drugs, only to find yourself back at square one just two years after stopping treatment. It’s a sobering reality that’s sparking conversations about the long-term effectiveness of these medications. While GLP-1 drugs like Ozempic, Wegovy, and Mounjaro have become go-to solutions for weight management, a groundbreaking study from the University of Oxford, published in The BMJ (https://www.bmj.com/content/392/bmj-2025-085304), reveals a surprising twist: their benefits may not last once you stop taking them. But here’s where it gets controversial—is relying solely on these drugs a sustainable solution, or are we missing a crucial piece of the puzzle?
Originally developed to manage diabetes, these medications mimic a hormone that curbs appetite and cravings, making them a hit even among those without diabetes. However, the Oxford study analyzed data from 37 trials involving 9,341 participants and found that people regain their original weight within an average of 1.7 years after discontinuing the drugs. And this is the part most people miss: weight regain occurs at a rate of 0.4 kg per month—four times faster than those who lose weight through behavioral programs focused on diet and exercise.
Dr. Sam West of the University of Oxford’s Nuffield Department of Primary Care Health Sciences explains, ‘These medicines are revolutionizing obesity treatment, but our research shows that weight regain after stopping is rapid. This isn’t a flaw in the drugs—it highlights obesity’s chronic, relapsing nature. It’s a reminder that short-term use without a comprehensive long-term strategy may fall short.’ The study also found that health risks tied to obesity, like high blood pressure and cholesterol, revert to pre-treatment levels within 1.4 years of stopping the medication.
Here’s the kicker: unlike cholesterol-lowering drugs, most weight-loss medications aren’t designed for indefinite use. Without medical or nutritional follow-up, patients risk regaining weight. Combining these drugs with behavioral programs could offer more lasting results, but this approach raises questions: Are we over-relying on quick fixes? Should we prioritize prevention over treatment? What do you think—are these drugs a game-changer, or do they need a rethink?
The study’s authors conclude, ‘The benefits of weight management medications fade quickly after treatment ends, underscoring the need for long-term strategies and primary prevention.’ This isn’t just about individual choices—it’s a call for systemic change. So, let’s spark a debate: Are we addressing obesity the right way, or is there a better path forward? Share your thoughts below!
